Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Pegylated Naloxone in the Treatment of Persistent Opioid-Induced Constipation in Patients with Hematological Malignancies
Volume: 16 Issue: 1
Author(s): Gregorio Antonio Brunetti, Giovanna Palumbo, Giorgia Annechini, Michelina Santopietro, Andrea Tendas*, Pasquale Niscola*Claudio Cartoni
Affiliation:
- Hematology Unit, S.Eugenio Hospital, Rome,Italy
- Hematology Unit, S.Eugenio Hospital, Rome,Italy
Export Options
About this article
Cite this article as:
Brunetti Antonio Gregorio, Palumbo Giovanna , Annechini Giorgia , Santopietro Michelina , Tendas Andrea *, Niscola Pasquale *, Cartoni Claudio , Pegylated Naloxone in the Treatment of Persistent Opioid-Induced Constipation in Patients with Hematological Malignancies, Cardiovascular & Hematological Agents in Medicinal Chemistry 2018; 16 (1) . https://dx.doi.org/10.2174/187152571601180910093543
DOI https://dx.doi.org/10.2174/187152571601180910093543 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Measles Virus as An Oncolytic Vector Platform
Current Gene Therapy Privileged Scaffolds Targeting Bromodomain-containing Protein 4
Current Topics in Medicinal Chemistry Histone Deacetylase Inhibitors: Molecular and Biological Activity as a Premise to Clinical Application
Current Drug Metabolism Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease
Current Gene Therapy Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies
Current Radiopharmaceuticals Imatinib and Its Successors – How Modern Chemistry has Changed Drug Development
Current Pharmaceutical Design Recent Trends in Targeted Anticancer Prodrug and Conjugate Design
Current Medicinal Chemistry Human Immunodeficiency Virus-Associated Malignancies: A Therapeutic Update
Current HIV Research Hypoxia Activated Prodrugs: Factors Influencing Design and Development
Current Medicinal Chemistry MicroRNAs in Lung Cancer and Lung Cancer Bone Metastases: Biomarkers for Early Diagnosis and Targets for Treatment
Recent Patents on Anti-Cancer Drug Discovery Cell Death Targeting Therapies in B Lymphoid Malignancies
Current Drug Targets VEGF Signal System: The Application of Antiangiogenesis
Current Medicinal Chemistry Editorial [Hot topic: Infectious Diseases and Hematology: At the Crossroad of Contemporary Therapy (Guest Editors: Hau C. Kwaan and Michael G. Ison)]
Infectious Disorders - Drug Targets Management of Inflammatory Bowel Disease Patients with a Cancer History
Current Drug Targets Targeted Cancer Therapy: The Next Generation of Cancer Treatment
Current Drug Discovery Technologies The Challenges in Moving from Ageing to Successful Longevity
Current Vascular Pharmacology Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay
Current Drug Targets Pharmacogenetics of Non-small Cell Lung Cancer (NSCLC): Time to "Work it Out"?
Current Pharmaceutical Design Monoclonal Antibody Therapy in Haematological Malignancies
Current Clinical Pharmacology